Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
18 Years and older, Male and Female
CL3-95031-007 (primary)
NCI-2024-03271
Summary
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind,
randomized, placebo-controlled study of orally administered ivosidenib. Participants are
required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1
(IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1,
2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined
during pre-screening/screening phase. Participant must have radiographic
progression/recurrence of disease according to Response Evaluation Criteria in Solid
Tumors (RECIST v1.1) and have received 0 to 1 prior systemic treatment regimen in the
advanced/metastatic setting for conventional chondrosarcoma. The primary endpoint is
progression-free survival (PFS) in Grades 1 and 2 participants. Key secondary endpoints
are PFS in all randomized participants, overall survival (OS) in Grades 1 and 2
participants, and OS in all randomized participants.
Participants who meet enrollment criteria will be randomized 1:1 to receive oral
ivosidenib 500mg once daily, or a matching placebo once daily.
Eligibility
- Have a histopathological diagnosis (fresh or banked tumor biopsy sample collected within the last 3 years) consistent with locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection.
- Have at least one BICR-confirmed measurable lesion as defined by RECIST v1.1. Participants who have received prior radiation therapy are eligible provided measurable disease falls outside of the treatment field or within the field and has shown =20% growth in size since post-treatment assessment.
- Have received 0 or 1 prior systemic treatment regimen in the advanced/metastatic setting for chondrosarcoma.
- Have radiographic progression/recurrence of disease according to RECIST v1.1 defined as:
- Radiographic progression of disease (local and/or distant) documented by 2 imaging assessments performed no more than 6 months (±2 weeks) apart within 12 months before randomization. OR
- Any recurrence of disease (local and/or distant) after complete surgical resection and documented by imaging within 6 months (±2 weeks) before randomization.
- Have documented IDH1 gene-mutated disease (from a fresh tumor biopsy or the most recent banked tumor tissue available that was sourced from either a primary or metastatic tumor lesion) based on central laboratory testing (R132C/L/G/H/S mutation variants tested)
- Have recovered from any clinically relevant sequelae and toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.